2861205-06-1

Product Details:

CasNo： 2861205-06-1

Molecular Formula： C82H110FN14O15.C10H19O2

Appearance： White to off-white Powder

Packing： Bottle

Throughput： 1KG/Month

Purity： 99%

Product Description

Generic Name: Enlicitide Decanoate

Chemical Class: Orally‑active macrocyclic‑peptide PCSK9 inhibitorMSD

Mechanism of Action: Enlicitide decanoate is a synthetic macrocyclic peptide. It selectively binds to circulating proprotein convertase subtilisin/kexin type 9 (PCSK9), blocks PCSK9‑mediated degradation of hepatic low‑density‑lipoprotein receptors (LDLR). Increased surface LDLR population enhances hepatic clearance of LDL‑C, non‑HDL‑C, apolipoprotein B and lipoprotein(a) from bloodstream, delivering robust lipid‑lowering effect.

Indications (FDA‑approved, Lipfendra®, July 2026)

As an adjunct to diet and exercise:

1. Reduce low‑density‑lipoprotein cholesterol (LDL‑C) in adult patients with primary hypercholesterolemia.
2. Reduce LDL‑C in adult patients with heterozygous familial hypercholesterolemia (HeFH).

Administration: Oral tablet, once‑daily dosing. May be used alone or combined with statins and other lipid‑lowering agentsDailyMed.

API Physicochemical Profile

• Appearance: White to off‑white solid powder
• Molecular Formula: \(\boldsymbol{C_{82}H_{110}FN_{14}O_{15}·C_{10}H_{19}O_2}\)
• Molecular Weight: 1722.09
• Solubility: Slightly soluble in water; soluble in organic solvents such as DMSO
• Storage condition for API powder: Store at ‑20 °C, tightly sealed, protect from moisture. Avoid repeated freeze‑thaw after dissolution.

Key Notes

• First‑in‑class oral PCSK9 inhibitor, alternative to injectable PCSK‑9 monoclonal antibodies (alirocumab, evolocumab).
• The marketed finished tablet contains enlicitide decanoate; research‑grade material is for laboratory use only, not for human clinical administration.